Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.
Tevimbra is under clinical development by BeiGene and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 32% phase transition success ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback